Regulatory Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy pharminent May 8, 2026
Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS pharminent May 5, 2026
Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026
Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation pharminent May 1, 2026
Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia pharminent April 30, 2026
Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy pharminent April 30, 2026
Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints pharminent April 30, 2026
Clinical Data AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data pharminent April 23, 2026
Policy / Pricing Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients pharminent April 22, 2026
M&A / Deals Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs pharminent April 21, 2026
Policy / Pricing Trump backs psychedelics for mental health in new executive order pharminent April 20, 2026
Clinical Data Roche to start new Elevidys study following setback in Europe pharminent April 16, 2026
Regulatory GSK again pulls application for leucovorin, touted by FDA as potential autism treatment pharminent April 10, 2026
M&A / Deals Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout pharminent March 31, 2026
Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup pharminent March 24, 2026
